TABLE 2.

Effects of torcetrapib on nonfasting plasma and TRL lipid levels^a

	Torcetrapib Alone		Atorvastatin + Torcetrapib
Parameter and Study Phaseb	120 mg QD (n = 9)	120 mg BID (n = 6)	120 mg QD (n = 9)	P value, Statin vsNonstatinc
Plasma lipids
Total cholesterol (mg/dl)
Placebo	195 ± 10	208 ± 12	142 ± 10	0.002
Torcetrapib	189 ± 10	204 ± 13	137 ± 7	< 0.001
Change (%)	−3 ± 3	−2 ± 4	−3 ± 3
P value	0.35	0.70	0.32
Triglycerides (mg/dl)
Placebo	277 ± 34	278 ± 39	169 ± 20	0.02
Torcetrapib	208 ± 26	258 ± 50	140 ± 20	0.04
Change (%)	−21 ± 8	−7 ± 8	−17 ± 9
P value	0.04	0.38	0.06
TRL lipids
Total cholesterol (mg/dl)
Placebo	32.5 ± 3.7	35.1 ± 5.7	17.3 ± 2.3	0.003
Torcetrapib	17.4 ± 2.1	20.4 ± 4.6	9.8 ± 1.6	0.01
Change (%)	−42 ± 8	−41 ± 7	−41 ± 8
P value	< 0.001	0.004	0.002
Cholesteryl ester (mg/dl)
Placebo	26.8 ± 3.4	29.6 ± 5.4	12.7 ± 1.7	0.002
Torcetrapib	6.9 ± 1.2	7.0 ± 2.4	3.5 ± 0.4	0.02
Change (%)	−73 ± 3	−78 ± 5	−69 ± 4
P value	< 0.001	0.002	< 0.001
Triglycerides (mg/dl)
Placebo	202 ± 24	208 ± 32	123 ± 20	0.03
Torcetrapib	160 ± 23	200 ± 45	103 ± 20	0.04
Change (%)	−17 ± 10	−6 ± 9	−16 ± 12
P value	0.08	0.46	0.10
TG/CE ratio
Placebo	8.0 ± 0.6	7.7 ± 0.9	10.1 ± 0.9	0.07
Torcetrapib	26.8 ± 3.9	47.1 ± 12.1	29.1 ± 4.1	0.69
Change (%)	229 ± 31	550 ± 216	193 ± 35
P value	< 0.001	0.02	0.001

BID, twice daily; CE, cholesteryl ester; TG, triglycerides; TRL, triglyceride-rich lipoprotein; QD, once daily. Bold face indicates significance.

^aEffects of torcetrapib on the composition of TRL, intermediate density lipoprotein (IDL), LDL, and HDL are shown in the supplementary data.

^bData are presented as mean ± SEM. Significance for comparison of absolute values with placebo phase was determined using a paired t-test, with triglycerides being log-transformed before statistical analysis.

^cSignificance for comparison between torcetrapib alone and atorvastatin + torcetrapib cohorts during placebo and torcetrapib 120 mg once daily phases was tested by a two-independent sample t-test.